Kuros Biosciences (CHIX:KURNZ) 3-Year Revenue Growth Rate : 69.00% (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Kuros Biosciences 3-Year Revenue Growth Rate?

Kuros Biosciences's Revenue per Share for the six months ended in Dec. 2024 was CHF1.15.

During the past 12 months, Kuros Biosciences's average Revenue per Share Growth Rate was 121.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was 69.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 69.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was -0.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Kuros Biosciences was 131.40% per year. The lowest was -78.40% per year. And the median was -1.40% per year.

Competitive Comparison of Kuros Biosciences's 3-Year Revenue Growth Rate

For the Medical Devices subindustry, Kuros Biosciences's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kuros Biosciences's 3-Year Revenue Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Kuros Biosciences's 3-Year Revenue Growth Rate falls into.

Save Embed

;

Save Embed

;

Kuros Biosciences 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Kuros Biosciences (CHIX:KURNz) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Kuros Biosciences 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Kuros Biosciences's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Kuros Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (CHIX:KURNz) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

CSBTF:USA 0RHR:UK YTSN:Germany KURN:Switzerland

Address

Wagistrasse 25, Schlieren, Zurich, CHE, 8952

Website

https://www.kurosbio.com

Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of inventive products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategies.

Kuros Biosciences Headlines

No Headlines